Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.63 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.61 |
| ▸ | WNT3A | P56704 | 3/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.54 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42245 | 0.98 | FLT3 (0.65) | FLT3CCNA2CDK2CCNA1KDM4E | |
| SCHEMBL29444537 | 0.98 | FLT3 (0.65) | FLT3CCNA2CDK2CCNA1KDM4E | |
| SCHEMBL27541852 | 0.96 | FLT3 (0.63) | FLT3CCNA2CDK2CCNA1KDM4E | |
| Hydrazine SCHEMBL27690059 | 0.94 | FLT3 (0.61) | FLT3CCNA2CDK2CCNA1KDM4E | |
| Hydrazine SCHEMBL27956766 | 0.93 | FLT3 (0.59) | FLT3CCNA2CDK2CCNA1KDM4E | |
| Methylene Chloride SCHEMBL28057236 | 0.91 | CTNNB1 (0.60) | FLT3CCNA2CDK2CCNA1KDM4E | |
| Benzamide SCHEMBL27732371 | 0.87 | CTNNB1 (0.60) | FLT3CCNA2CDK2CCNA1KDM4E | |
| SCHEMBL4464792 | 0.85 | KDM4E (0.68) | FLT3CCNA2CDK2CCNA1KDM4E | |
| SCHEMBL5908296 | 0.85 | KDM4E (0.57) | FLT3CCNA2CDK2CCNA1KDM4E | |
| Indole SCHEMBL9100070 | 0.84 | FLT3 (0.51) | FLT3CCNA2CDK2CCNA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101239950-A | 1-(substituted benzoyl)-indazole-3-carboxylate or amides compounds thereof, synthesis and application thereof | UNIV PLA 2ND MILITARY MEDICAL (CN) | 2008-08-13 | — | — | CN | claimed |
| WO-2023169170-A1 | HETEROCYCLIC COMPOUND AS SHP2 INHIBITOR, COMPOSITION COMPRISING HETEROCYCLIC COMPOUND, AND METHOD USING SAME | 捷思英达控股有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-108699038-A | Loop coil heptane salicylamide and related compound as Rock inhibitor | 百时美施贵宝公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-101239950-B | 1-(substituted benzoyl)-indazole-3-carboxylate or amides compounds thereof, synthesis and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2011-01-19 | — | — | CN | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| EP-1957478-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| CN-101239950-A | 1-(substituted benzoyl)-indazole-3-carboxylate or amides compounds thereof, synthesis and application thereof | UNIV PLA 2ND MILITARY MEDICAL (CN) | 2008-08-13 | — | — | CN | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| CN-1262681-A | 4,5-dihydro-[1H]-benz [g] indazole-3-carboxylic acid derivatives | TEIKOKU HORMONE MFG CO LTD (JP) | 2000-08-09 | — | — | CN | disclosed |
| EP-0558923-B1 | Diazabicyclo derivatives as 5-HT3 antagonists | NISSHIN FLOUR MILLING CO (JP) | 2000-05-24 | — | — | EP | disclosed |
| US-5344831-A | Antiemetics for treatment of nausea from chemotherapy | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| US-5256656-A | Antiserotonine agent | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| EP-0558923-A1 | Diazabicyclo derivatives as 5-HT3 antagonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-09-08 | — | — | EP | disclosed |
| US-5187166-A | Also useful as antipsychotic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | FLT3 346/4885CCNA2 2/4885CDK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.